Soni A
Int J Health Econ Manag. 2024; 24(4):481-515.
PMID: 39093341
DOI: 10.1007/s10754-024-09382-3.
Frakes M, Wasserman M
Am Econ J Econ Policy. 2024; 15(3):151-183.
PMID: 38213756
PMC: 10783444.
DOI: 10.1257/pol.20200703.
Fan C, Song X, Li C
Healthcare (Basel). 2023; 11(22).
PMID: 37998407
PMC: 10671039.
DOI: 10.3390/healthcare11222916.
Alpert A, Lakdawalla D, Sood N
J Public Econ. 2023; 221.
PMID: 37275770
PMC: 10237358.
DOI: 10.1016/j.jpubeco.2023.104860.
Liu J, Zhang Y, Kaplan C
Health Econ. 2022; 32(3):639-653.
PMID: 36399360
PMC: 9898097.
DOI: 10.1002/hec.4637.
Pharmaceutical policies: effects of regulating drug insurance schemes.
Pantoja T, Penaloza B, Cid C, Herrera C, Ramsay C, Hudson J
Cochrane Database Syst Rev. 2022; 5:CD011703.
PMID: 35502614
PMC: 9062704.
DOI: 10.1002/14651858.CD011703.pub2.
The effect on dental care utilization from transitioning pediatric Medicaid beneficiaries to managed care.
Nasseh K, Bowblis J
Health Econ. 2022; 31(6):1103-1128.
PMID: 35322488
PMC: 9314593.
DOI: 10.1002/hec.4496.
How increasing medical access to opioids contributes to the opioid epidemic: Evidence from Medicare Part D.
Powell D, Pacula R, Taylor E
J Health Econ. 2020; 71:102286.
PMID: 32193022
PMC: 7231644.
DOI: 10.1016/j.jhealeco.2019.102286.
The impact of Medicare part D on income-related inequality in pharmaceutical expenditure.
Carvalho N, Petrie D, Chen L, Salomon J, Clarke P
Int J Equity Health. 2019; 18(1):57.
PMID: 30992000
PMC: 6469203.
DOI: 10.1186/s12939-019-0955-9.
Strategic Formulary Design in Medicare Part D Plans.
Lavetti K, Simon K
Am Econ J Econ Policy. 2019; 10(3):154-192.
PMID: 30662681
PMC: 6335045.
DOI: 10.1257/pol.20160248.
Firm responses to targeted consumer incentives: Evidence from reference pricing for surgical services.
M Whaley C, Brown T
J Health Econ. 2018; 61:111-133.
PMID: 30114564
PMC: 10830325.
DOI: 10.1016/j.jhealeco.2018.06.012.
Simplifying The Medicare Plan Finder Tool Could Help Older Adults Choose Lower-Cost Part D Plans.
McGarry B, Maestas N, Grabowski D
Health Aff (Millwood). 2018; 37(8):1290-1297.
PMID: 30080456
PMC: 6417418.
DOI: 10.1377/hlthaff.2018.0145.
The effects of state-level pharmacist regulations on generic substitution of prescription drugs.
Song Y, Barthold D
Health Econ. 2018; 27(11):1717-1737.
PMID: 29992674
PMC: 6172151.
DOI: 10.1002/hec.3796.
Selection in Health Insurance Markets and Its Policy Remedies.
Geruso M, Layton T
J Econ Perspect. 2018; 31(4):23-50.
PMID: 29465215
PMC: 10898225.
DOI: 10.1257/jep.31.4.23.
The impact of health insurance expansion on physician treatment choice: Medicare Part D and physician prescribing.
Hu T, Decker S, Chou S
Int J Health Econ Manag. 2017; .
PMID: 28168448
PMC: 6606398.
DOI: 10.1007/s10754-017-9211-2.
The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
Park T, Jung J
J Manag Care Spec Pharm. 2016; 23(1):5-12.
PMID: 28025927
PMC: 10398226.
DOI: 10.18553/jmcp.2017.23.1.5.
Beyond Statistics: The Economic Content of Risk Scores.
Einav L, Finkelstein A, Kluender R, Schrimpf P
Am Econ J Appl Econ. 2016; 8(2):195-224.
PMID: 27429712
PMC: 4945120.
DOI: 10.1257/app.20150131.
The anticipatory effects of Medicare Part D on drug utilization.
Alpert A
J Health Econ. 2016; 49:28-45.
PMID: 27372577
PMC: 10621617.
DOI: 10.1016/j.jhealeco.2016.06.004.
Payments For Opioids Shifted Substantially To Public And Private Insurers While Consumer Spending Declined, 1999-2012.
Zhou C, Florence C, Dowell D
Health Aff (Millwood). 2016; 35(5):824-31.
PMID: 27140988
PMC: 4955937.
DOI: 10.1377/hlthaff.2015.1103.
THE RESPONSE OF DRUG EXPENDITURE TO NON-LINEAR CONTRACT DESIGN: EVIDENCE FROM MEDICARE PART D.
Einav L, Finkelstein A, Schrimpf P
Q J Econ. 2016; 130(2):841-899.
PMID: 26769984
PMC: 4710380.
DOI: 10.1093/qje/qjv005.
